13F Holdings
中文EN

HRTX HERON THERAPEUTICS, INC. /DE/

Pharmaceutical Preparations · Nasdaq · SEC CIK 818033 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.4%
TTM net income YoY-58.8%
TTM EPS YoY-22.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR—

Margins

Gross margin71.5%
Operating margin-5.7%
Net margin-14.5%
FCF margin-9.7%
EBITDA margin-4.4%

Returns

ROE-217.8%
ROA-9.0%
ROIC (approx.)—
Asset turnover0.62x

Leverage & solvency

Liabilities / assets97.9%
Debt / equity0.00x
Current ratio2.33x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$154.90M$144.28M$127.04M$107.67M$86.35M
Cost of revenue$41.35M$38.65M$65.11M$54.87M$46.02M
Gross profit$113.56M$105.64M$61.94M$52.80M$40.33M
R&D expense$12.43M$16.68M$39.13M$82.70M$130.82M
SG&A expense$54.60M$53.40M$65.78M$62.24M$40.15M
Operating income-$2.54M-$11.53M-$110.61M-$174.66M-$217.83M
Interest expense$9.61M$6.03M$3.87M$2.47M$2.41M
Income tax$0$0$0$0$0
Net income-$20.20M-$13.58M-$110.56M-$182.02M-$220.68M
EBITDA-$224,000-$9.04M-$107.72M-$171.77M-$214.81M
EPS (basic)-0.12-0.09-0.80-1.67-2.24
EPS (diluted)-0.12-0.09-0.80-1.67-2.24
Weighted avg. shares (diluted)166.71M152.45M138.13M108.88M98,471
Balance sheet
Cash & equivalents$28.65M$25.80M$28.68M$15.36M$90.54M
Short-term investments$17.98M$33.48M$51.73M$69.49M$67.04M
Receivables$89.59M$78.88M$60.14M$52.05M$35.50M
Inventory$92.75M$53.16M$42.11M$54.57M$48.38M
Current assets$238.07M$209.01M$188.77M$205.44M$254.42M
PP&E, net$12.40M$14.86M$20.17M$22.16M$23.73M
Total assets$255.88M$233.15M$222.51M$250.95M$305.71M
Current liabilities$96.10M$91.46M$79.69M$82.36M$71.06M
Total liabilities$241.54M$266.80M$256.48M$237.38M$228.14M
Shareholders' equity$14.33M-$33.65M-$33.97M$13.57M$77.57M
Shares outstanding188.31M152.13M150.29M119.15M102.00M
Cash flow statement
Operating cash flow-$27.59M-$22.53M-$58.79M-$146.91M-$203.35M
Capital expenditure$317,000$1.71M$1.54M$1.82M$3.02M
Free cash flow-$27.91M-$24.23M-$60.33M-$148.74M-$206.38M
Investing cash flow$16.01M$18.71M$18.00M-$3.32M$32.73M
Financing cash flow$14.43M$940,000$54.11M$75.06M$156.03M
Depreciation & amortization$2.31M$2.49M$2.90M$2.89M$3.02M
Stock-based compensation$10.34M$12.96M$32.85M$42.98M$46.85M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.